News | Brachytherapy Systems | October 21, 2015

Long-term Data Supports Xoft System for Early-Stage Breast, Nonmelanoma Skin Cancer

iCAD presents series of clinical studies supporting electronic brachytherapy system for multiple applications at ASTRO 2015

iCAD, Xoft Axxent, electronic brachytherapy, eBx, clinical studies, ASTRO 2015, radiation therapy

Xoft Axxent image courtesy of iCAD Inc.

October 21, 2015 — iCAD Inc. presented updated clinical data, hosted in-booth clinician presentations and showcased the latest in radiation technology at the American Society for Radiation Oncology (ASTRO) meeting in San Antonio, Texas, Oct. 18-21, 2015.

At the meeting, Ajay Bhatnagar, M.D., and Parag Sanghvi, M.D., presented posters with updated data on the use of electronic brachytherapy (eBx) in the treatment of nonmelanoma skin cancer (NMSC). Their data reflect treatment with the Xoft System for a total of 342 patients with 466 NMSC lesions, resulting in excellent cosmesis and few recurrences, with a mean follow-up time of 16.5 months and 11.8 months, respectively.

Alam M. Nisar Syed, M.D., and Adam Dickler, M.D., also presented posters with data supporting use of the Xoft System for the treatment of early-stage breast cancer. Their data reflect treatment of 136 breast cancer lesions with the system, showing positive clinical results, excellent to good cosmesis, few recurrences and a low rate of low-grade adverse events.

Gary Proulx, M.D., medical director, Exeter Hospital Radiation Oncology, clinical associate professor, Massachusetts General Hospital, discussed his clinical experience with intraoperative radiation therapy (IORT) and the Xoft System at the Xoft booth, where the system and its cervical applicator, now commercially available, were on display. Visitors also had an opportunity to see an investigational line of applicators for IORT, shown as works in progress, for the treatment of prostate, head/neck, abdominal and brain cancers, among others.

The Xoft System is an isotope-free radiation treatment that is U.S. Food and Drug Administration (FDA)-cleared, CE marked and licensed in Canada for the treatment of cancer anywhere in the body. It utilizes a proprietary miniaturized X-ray as the radiation source that delivers precise treatment directly to cancerous areas while sparing healthy tissue and organs. The system requires only minimal shielding and therefore does not require room redesign or construction investment. Minimal shielding also allows medical personnel to remain in the room with the patient during treatment. The mobility of the system makes it easy to treat patients at multiple locations and to easily store the system when not in use.

For more information: www.icadmed.com, www.xoftinc.com

Related Content

New Method Improves Ability to Measure and Maximize Radiation Therapy Dose
News | Radiation Therapy | May 14, 2019
Delivering just the right dose of radiation for cancer patients is a delicate balance in their treatment regime....
Sponsored Content | Videos | Radiation Oncology | May 13, 2019
At ASTRO 2018, Accuray showcased new patient-fi
Radiotherapy After Chemo May Improve Survival in Advanced Hodgkin's Lymphoma Patients
News | Radiation Therapy | May 10, 2019
Patients with advanced Hodgkin's lymphoma who have large tumors at the time of diagnosis may benefit from radiotherapy...
IBA Partnering to Develop Advanced Digital Proton Therapy Technologies in Belgium
News | Proton Therapy | May 10, 2019
IBA (Ion Beam Applications SA) announced a research agreement with Skandionkliniken, Université Catholique de Louvain...
A CyberHeart cardiac ablation radiotherapy treatment plan showing where the radiation beam will ablate for a noninvasive pulmonary vein isolation procedure. Varian acquires, buys, purchases Cyberheart.

A CyberHeart cardiac ablation radiotherapy treatment plan showing where the radiation beams will ablate for a noninvasive pulmonary vein isolation procedure to treat an arrhythmia.

Feature | Radiation Therapy | May 10, 2019
May 10, 2019 — Radiation oncology vendor Varian announced it acquired the start-up company CyberHeart, which has deve
The novel nanoparticle is designed to enhance radiation killing of cancer cells in the radiation resistant low-oxygen tumor core

The novel nanoparticle is designed to enhance radiation killing of cancer cells in the radiation resistant low-oxygen tumor core. Credit: Wenpei Fan, LOMIN Laboratory, NIBIB.

News | Radiation Therapy | May 08, 2019
Radiation kills tumors by creating oxygen free radicals that damage the tumor DNA. However, the lack of oxygen in the...
Netherlands Proton Therapy Center Delivers First Clinical Flash Irradiation
News | Proton Therapy | May 02, 2019
IBA (Ion Beam Applications SA) recently announced the first Flash irradiation in an IBA proton therapy gantry treatment...
Artificial intelligence (AI) was again the hottest topic in radiology, with 11 of the top 20 pieces of content this month relating to AI. These images are a few of the AI technologies highlighted in ITN Editor's Choice video of the most innovative AI technologies highlighted at RSNA 2018.

Artificial intelligence (AI) was again the hottest topic in radiology, with 11 of the top 20 pieces of content this month relating to AI. These images are a few of the AI technologies highlighted in ITN Editor's Choice video of the most innovative AI technologies highlighted at RSNA 2018. 

Feature | May 01, 2019
May 1, 2019 — Here is the list of the most popular content on the Imaging Technology New (ITN) magazine webs
Pencil Beam Scanning Better Protects Children With Brain Tumors
News | Proton Therapy | May 01, 2019
A comparison of three types of radiotherapy for children's brain tumors suggests a type of proton therapy called pencil...
Researchers Identify Ways to Predict and Avoid Radiotherapy Side Effects
News | Radiation Therapy | April 30, 2019
New research has shown a combination of biological markers and certain genetic changes can predict radiation...